T G Deloughery

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi Anticoagulant therapy in special circumstances
    T G Deloughery
    Hematology OP 28, Oregon Health Sciences University, Portland, 97201 3098, USA
    Curr Cardiol Rep 2:74-9. 2000
  2. ncbi Venous thrombotic emergencies
    Thomas G Deloughery
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, L586, Portland, OR 97201 3098, USA
    Emerg Med Clin North Am 27:445-58. 2009
  3. ncbi Estrogen and thrombosis: controversies and common sense
    Thomas G Deloughery
    Knight Cancer Center, Hematology Laboratory Medicine, Departments of Medicine, Pathology, and Pediatrics, Oregon Health Sciences University, Portland, OR 97229 3098, USA
    Rev Endocr Metab Disord 12:77-84. 2011
  4. ncbi Practical aspects of the oral new anticoagulants
    Thomas G Deloughery
    Division of Hematology Medical Oncology, Department of Medicine, Oregon Health Sciences University, Portland, 97201 3098, USA
    Am J Hematol 86:586-90. 2011
  5. ncbi Critical care clotting catastrophies
    Thomas G Deloughery
    Oregon Health and Science University, Hematology L586, 3181 SW Sam Jackson Park Road, Portland, OR 97201 3098, USA
    Crit Care Clin 21:531-62. 2005
  6. ncbi Management of bleeding emergencies: when to use recombinant activated factor VII
    Thomas G Deloughery
    Division of Hematology Medical Oncology, Department of Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201 3098, USA
    Expert Opin Pharmacother 7:25-34. 2006
  7. ncbi Update in hematology
    Thomas G Deloughery
    Divisions of Hematology/Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239-3098, USA
    Ann Intern Med 147:717-24. 2007
  8. ncbi Management of acquired bleeding problems in cancer patients
    Thomas G Deloughery
    Division of Hematology, Department of Medicine, L586, Oregon Health and Science University, Portland, OR 97201 3098, USA
    Emerg Med Clin North Am 27:423-44. 2009
  9. ncbi Thrombocytopenia and other hot topics
    Thomas G Deloughery
    Oregon Health Sciences University, Portland, 97239 3098, USA
    Am J Clin Oncol 32:S13-7. 2009
  10. ncbi Venous thrombotic emergencies
    Thomas G Deloughery
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, L586, 3181 SW Sam Jackson Park Road, Portland, OR 97201 3098, USA
    Hematol Oncol Clin North Am 24:487-500. 2010

Detail Information

Publications33

  1. ncbi Anticoagulant therapy in special circumstances
    T G Deloughery
    Hematology OP 28, Oregon Health Sciences University, Portland, 97201 3098, USA
    Curr Cardiol Rep 2:74-9. 2000
    ....
  2. ncbi Venous thrombotic emergencies
    Thomas G Deloughery
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, L586, Portland, OR 97201 3098, USA
    Emerg Med Clin North Am 27:445-58. 2009
    ..Rarer entities, such as cerebral vein thrombosis and Budd-Chiari syndrome, are also reviewed...
  3. ncbi Estrogen and thrombosis: controversies and common sense
    Thomas G Deloughery
    Knight Cancer Center, Hematology Laboratory Medicine, Departments of Medicine, Pathology, and Pediatrics, Oregon Health Sciences University, Portland, OR 97229 3098, USA
    Rev Endocr Metab Disord 12:77-84. 2011
    ..For women with bleeding disorders these prothrombotic changes can help decrease bleeding complications. There is now also abundant data on future management of patients with estrogen related thrombosis...
  4. ncbi Practical aspects of the oral new anticoagulants
    Thomas G Deloughery
    Division of Hematology Medical Oncology, Department of Medicine, Oregon Health Sciences University, Portland, 97201 3098, USA
    Am J Hematol 86:586-90. 2011
    ..Also to be discussed are practical aspects of use of these new agents such monitoring, reversal, and use before procedures...
  5. ncbi Critical care clotting catastrophies
    Thomas G Deloughery
    Oregon Health and Science University, Hematology L586, 3181 SW Sam Jackson Park Road, Portland, OR 97201 3098, USA
    Crit Care Clin 21:531-62. 2005
    ..These include heparin induced thrombocytopenia, thrombotic thrombocytopenic purpura, and disseminated intravascular coagulation...
  6. ncbi Management of bleeding emergencies: when to use recombinant activated factor VII
    Thomas G Deloughery
    Division of Hematology Medical Oncology, Department of Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201 3098, USA
    Expert Opin Pharmacother 7:25-34. 2006
    ..Although most of the reports on rVIIa are anecdotes and case series, there is increasing data for clinical trials to help guide usage...
  7. ncbi Update in hematology
    Thomas G Deloughery
    Divisions of Hematology/Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239-3098, USA
    Ann Intern Med 147:717-24. 2007
  8. ncbi Management of acquired bleeding problems in cancer patients
    Thomas G Deloughery
    Division of Hematology, Department of Medicine, L586, Oregon Health and Science University, Portland, OR 97201 3098, USA
    Emerg Med Clin North Am 27:423-44. 2009
    ..Specific issue including coagulation defects, thrombocytopenia, platelet dysfunction, bleeding complications of specific hematological malignancies and due to anticoagulation, are discussed...
  9. ncbi Thrombocytopenia and other hot topics
    Thomas G Deloughery
    Oregon Health Sciences University, Portland, 97239 3098, USA
    Am J Clin Oncol 32:S13-7. 2009
    ..Given the ongoing clinical questions and new drugs, anticoagulant therapy in patients with cancer promises to have an exciting future...
  10. ncbi Venous thrombotic emergencies
    Thomas G Deloughery
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, L586, 3181 SW Sam Jackson Park Road, Portland, OR 97201 3098, USA
    Hematol Oncol Clin North Am 24:487-500. 2010
    ..Rarer entities, such as cerebral vein thrombosis and Budd-Chiari syndrome, are also reviewed...
  11. ncbi Management of acquired bleeding problems in cancer patients
    Thomas G Deloughery
    Divisions of Hematology and Medical Oncology, Department of Medicine, L586, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201 3098, USA
    Hematol Oncol Clin North Am 24:603-24. 2010
    ..Specific issues including coagulation defects, thrombocytopenia, platelet dysfunction, and bleeding complications of specific hematological malignancies due to anticoagulation, are discussed...
  12. ncbi Logistics of massive transfusions
    Thomas G Deloughery
    Division of Hematology, Oregon Health Sciences University, Portland, OR 97201 3098, USA
    Hematology Am Soc Hematol Educ Program 2010:470-3. 2010
    ..The proper management of massive transfusions-whether they are in trauma patients or other bleeding patients-requires coordination of the personnel in the surgical suite or the emergency department, the blood bank, and laboratory...
  13. ncbi Venous thromboembolism in the ICU and reversal of bleeding on anticoagulants
    Thomas G Deloughery
    Oregon Health and Science University, Hematology L586, 3181 SW Sam Jackson Park Road, Portland, OR 97201 3098, USA
    Crit Care Clin 21:497-512. 2005
    ..The increased use of antithrombotic agents has led to an increased number of patients who experience bleeding complications on anticoagulant therapy. This review also addresses the methods of reversing various anticoagulants...
  14. ncbi Coagulation abnormalities and cardiovascular disease
    T G Deloughery
    Department of Medicine, Oregon Health Sciences University, Portland 97201 3098, USA
    Curr Opin Lipidol 10:443-8. 1999
    ..Pathogenic polymorphisms in the platelet fibrinogen and collagen receptors remains an area of intense research interest. Finally, it has been shown that lipoproteins can act as mediators of coagulation processes...
  15. ncbi Moderate hypoxia suppresses exercise-induced procoagulant changes
    Thomas G Deloughery
    Division of Hematology Medical Oncology, Department of Medicine, Oregan Health and Science Univerity, Portland, OR 97239 3098, USA
    Br J Haematol 125:369-72. 2004
    ..Thus, it appears that hypoxia may exert an antithrombotic effect by both damping exercise-induced procoagulant changes and stimulating fibrinolysis...
  16. ncbi Coagulation defects in trauma patients: etiology, recognition, and therapy
    Thomas G Deloughery
    Division of Medical Oncology, L586 Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201 3098, USA
    Crit Care Clin 20:13-24. 2004
    ..Attention also should be paid to any other correctable factors such as hypothermia. Finally, pre-existing disorders can influence the patient's hemostasis greatly and may require specific therapies...
  17. ncbi Management of bleeding with uremia and liver disease
    T G Deloughery
    Hematology OP 28, Oregon Health Sciences University, Portland 97201 3098, USA
    Curr Opin Hematol 6:329-33. 1999
    ..Careful assessment of both the patient's clinical situation and laboratory findings is important for tailoring therapy of the bleeding patient...
  18. ncbi Pulmonary hemorrhage in a hemophiliac simulating a lung neoplasm
    M E O'Dwyer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland, Oregon 97201, USA
    Am J Hematol 64:299-302. 2000
    ..This is the first report of symptomatic pulmonary hemorrhage in a patient with hemophilia B. Hemorrhage into a pre-existing bulla can simulate a primary lung neoplasm...
  19. ncbi Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model
    E A Neuwelt
    Department of Neurology, Oregon Health Sciences University, Portland, Oregon 97201, USA
    Cancer Res 61:7868-74. 2001
    ....
  20. ncbi First episode and recurrent venous thromboembolism: who is identifiably at risk?
    Timothy K Liem
    Division of Vascular Surgery, Oregon Health and Science University, OP 11, 3181 SW Sam Jackson Park Road, Portland, OR, USA
    Semin Vasc Surg 21:132-8. 2008
    ....
  21. ncbi Coagulation management in massive bleeding
    Matthew J Griffee
    Department of Anesthesiology and Perioperative Medicine, USA
    Curr Opin Anaesthesiol 23:263-8. 2010
    ..To update readers on recent literature regarding treatment of coagulopathy for patients with life-threatening bleeding, highlighting emerging therapeutic options, controversial topics, and ongoing clinical trials...
  22. ncbi Pulmonary and intracerebral plasmacytomas in a patient without multiple myeloma: a case report
    Brandon Hayes-Lattin
    Division of Hematology and Medical Oncology, Oregon Health and Science University, The OHSU Cancer Institute, Portland, Oregon 97202, USA
    Am J Hematol 73:131-4. 2003
    ..Extramedullary plasmacytoma of the lung or brain parenchyma is rare. We report herein a case of extramedullary plasmacytoma involving both the lung and parenchymal brain. We review the literature, comparing and contrasting the current case...
  23. ncbi Safety of inferior vena cava filter retrieval in anticoagulated patients
    Hanno Hoppe
    Dotter Interventional Institute, Oregon Health and Science University, L 605, 3181 SW Sam Jackson Park Rd, Portland, OR 97239 3098, USA
    Chest 132:31-6. 2007
    ....
  24. ncbi High dose calcitriol may reduce thrombosis in cancer patients
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
    Br J Haematol 135:392-4. 2006
    ..In vitro and vitamin D receptor (VDR) knockout mouse studies predict that nanomolar concentrations of calcitriol may act as an antithrombotic agent. We report the first clinical observation that supports this hypothesis in humans...
  25. ncbi Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature
    Jennifer L Lycette
    Division of Hematology and Medical Oncology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Mailcode L586, Portland, OR 97239, USA
    Breast Cancer Res Treat 99:249-55. 2006
    ....
  26. ncbi A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer
    Charles D Blanke
    Oregon Health and Science University Cancer Institute, Portland, OR, USA
    Prostaglandins Other Lipid Mediat 75:169-72. 2005
    ..5-FU and leucovorin did not affect COX-2 inhibition by celecoxib. Preliminary data suggest it is safe to combine celecoxib with standard chemotherapeutic agents, in treatment of patients with colorectal cancer...
  27. ncbi Symptomatic perioperative venous thromboembolism is a frequent complication in patients with a history of deep vein thrombosis
    Timothy K Liem
    Division of Vascular Surgery and the Division of Hematology Oncology, Oregon Health and Science University, Portland, Ore 97239, USA
    J Vasc Surg 52:651-7. 2010
    ..This study determined the incidence and risk factors for symptomatic perioperative VTE in patients with a prior diagnosis of DVT...
  28. ncbi Recurrent thromboembolic disease following splenectomy for pyruvate kinase deficiency
    R Chou
    Department of Medicine, Portland Veteran s Affairs Medical Center, Oregon Health Sciences University, Portland, Oregon, USA
    Am J Hematol 67:197-9. 2001
    ....
  29. ncbi Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease
    T G Deloughery
    Department of Medicine, Oregon Health Sciences University, Portland 97201 3098, USA
    Circulation 94:3074-8. 1996
    ..We determined the prevalence of this mutation in many subjects with and without vascular disease and related it to homocysteine and folate levels...
  30. ncbi The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
    Cancer 107:489-96. 2006
    ..Although race alone was not a strong predictor of death or disease progression, the effect of the baseline HGB level on overall and progression-free survival varied significantly by race...
  31. ncbi Evolutionary conservation of the AU-rich 3' untranslated region of messenger RNA
    M A Asson-Batres
    Department of Medicine, Oregon Health Sciences University, Portland 97201
    Proc Natl Acad Sci U S A 91:1318-22. 1994
    ....
  32. ncbi Phase II study of transdermal estradiol in androgen-independent prostate carcinoma
    Lisa B Bland
    Division of Urology, Oregon Health and Science University and Portland Veterans Affairs Medical Center, Portland, Oregon, 97239, USA
    Cancer 103:717-23. 2005
    ..CONCLUSIONS: In patients with APIC, TDE was well tolerated and produced a modest response rate, but was not associated with thromboembolic complications or clinically important changes in several coagulation factors...
  33. ncbi Effects of Ginkgo biloba on exhaled nasal nitric oxide during normobaric hypoxia in humans
    Casey Jowers
    Oregon Health and Sciences University, Portland, OR, USA
    High Alt Med Biol 5:445-9. 2004
    ..Our results suggest that Ginkgo biloba may act to reduce AMS through an effect on NO metabolism...